ArticleChemistry, an Asian journal2012
Self-assembled aptamer-based drug carriers for bispecific cytotoxicity to cancer cells.
Article in Chemistry, an Asian journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Are we there yet with XNA aptamers?RSC advances · 2026Review
- Aptamer-Based Cancer Cell Analysis and Treatment.ChemistryOpen · 2022Review
- Recent advances in understanding oligonucleotide aptamers and their applications as therapeutic agents.3 Biotech · 2020Review
- Current Aspects of siRNA Bioconjugate for In Vitro and In Vivo Delivery.Molecules (Basel, Switzerland) · 2019Review
- Novel insights into the role of aptamers in the fight against cancer.Journal of cancer research and clinical oncology · 2019Review
- Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective.Journal of molecular medicine (Berlin, Germany) · 2018Review
- Article
- Nucleic Acid Aptamers: Emerging Applications in Medical Imaging, Nanotechnology, Neurosciences, and Drug Delivery.International journal of molecular sciences · 2017Review
- Advances in the development of aptamer drug conjugates for targeted drug delivery.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2017Review
- Aptamer-Mediated Targeted Delivery of Therapeutics: An Update.Pharmaceuticals (Basel, Switzerland) · 2016Review
- Aptamer-Functionalized Nanoparticles as "Smart Bombs": The Unrealized Potential for Personalized Medicine and Targeted Cancer Treatment.Targeted oncology · 2015Review
- Aptamer-Drug Conjugates.Bioconjugate chemistry · 2015Review
- Self-assembled Multifunctional DNA Nanoflowers for the Circumvention of Multidrug Resistance in Targeted Anticancer Drug Delivery.Nano research · 2015Article
- Preparation and biomedical applications of programmable and multifunctional DNA nanoflowers.Nature protocols · 2015Article
- Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine.Theranostics · 2015Review
- Oligonucleotide aptamers: new tools for targeted cancer therapy.Molecular therapy. Nucleic acids · 2014Article
- Gold-Coated FeAdvanced functional materials · 2014Article
- Automated modular synthesis of aptamer-drug conjugates for targeted drug delivery.Journal of the American Chemical Society · 2014Article
- Progress in aptamer-mediated drug delivery vehicles for cancer targeting and its implications in addressing chemotherapeutic challenges.Theranostics · 2014Review
- Building a multifunctional aptamer-based DNA nanoassembly for targeted cancer therapy.Journal of the American Chemical Society · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Monovalent aptamers can deliver drugs to target cells by specific recognition. However, different cancer subtypes are distinguished by heterogeneous biomarkers and one single aptamer is unable to recognize all clinical samples from different patients with even the same type of cancers. To address heterogeneity among cancer subtypes for targeted drug delivery, as a model, we developed a drug carrier with a broader recognition range of cancer subtypes. This carrier, sgc8c-sgd5a (SD), was self-assembled from two modified monovalent aptamers. It showed bispecific recognition abilities to target cells in cell mixtures; thus broadening the recognition capabilities of its parent aptamers. The self-assembly of SD simultaneously formed multiple drug loading sites for the anticancer drug doxorubicin (Dox). The Dox-loaded SD (SD-Dox) also showed bispecific abilities for target cell binding and drug delivery. Most importantly, SD-Dox induced bispecific cytotoxicity in target cells in cell mixtures. Therefore, by broadening the otherwise limited recognition capabilities of monovalent aptamers, bispecific aptamer-based drug carriers would facilitate aptamer applications for clinically heterogeneous cancer subtypes that respond to the same cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.